Evidence map›Paper›PMID 39667035›Full record

ArticleProtein engineering, design & selection : PEDS2025

Optimized single-cell gates for yeast display screening.

Xiaoli Pan, Matheus O de Souza, Francisco M Figueiras, Aric Huang, Bailey B Banach, Jacy R Wolfe, Azady Pirhanov, Bharat Madan, Brandon J DeKosky

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Protein engineering, design & selection : PEDS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaoli PanThe Ragon Institute of Mass General, MIT, and Harvard, 600 Main St, Cambridge, MA 02139, USA.
Matheus O de SouzaThe Ragon Institute of Mass General, MIT, and Harvard, 600 Main St, Cambridge, MA 02139, USA.
Francisco M FigueirasThe Ragon Institute of Mass General, MIT, and Harvard, 600 Main St, Cambridge, MA 02139, USA.
Aric HuangDepartment of Pharmaceutical Chemistry, The University of Kansas, 2093 Constant Ave, Lawrence, KS 66045, USA.
Bailey B BanachBioengineering Graduate Program, The University of Kansas, 1530 W 15th St., Lawrence, KS 66045, USA.
Jacy R WolfeDepartment of Pharmaceutical Chemistry, The University of Kansas, 2093 Constant Ave, Lawrence, KS 66045, USA.
Azady PirhanovThe Ragon Institute of Mass General, MIT, and Harvard, 600 Main St, Cambridge, MA 02139, USA.
Bharat MadanThe Ragon Institute of Mass General, MIT, and Harvard, 600 Main St, Cambridge, MA 02139, USA.
Brandon J DeKoskyThe Ragon Institute of Mass General, MIT, and Harvard, 600 Main St, Cambridge, MA 02139, USA.ORCID 0000-0001-6406-0836

Funding

Dissecting the mechanisms of HIV resistance in vivo to broadly neutralizing antibodiesU01AI169587 · NIAID · UNIVERSITY OF MINNESOTA · PI Priyamvada Acharya, Brandon James DeKosky · 2022 to 2026
$7.8M
Potent broadly neutralizing antibody development against the HIV-1 fusion peptide epitopeR01AI181684 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Brandon James DeKosky · 2023 to 2026
$3.0M
Comprehensive analysis of human adaptive immune receptors to elucidate correlates of Epstein-Barr virus disease suppressionDP5OD023118 · OD · UNIVERSITY OF KANSAS LAWRENCE · PI DEKOSKY, BRANDON JAMES · 2016 to 2022
$2.2M
Rapid antibody screening systems to identify and engineer antiviral protectionR21AI166396 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI DEKOSKY, BRANDON JAMES · 2022 to 2023
$850k
Comprehensive molecular and functional analyses of anti-HIV-1 broadly neutralizing antibody repertoiresR21AI143407 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI DEKOSKY, BRANDON JAMES, FORREST, MARCUS LAIRD · 2019 to 2020
$435k
NIAID NIH HHS R01 AI181684NIAID NIH HHS R21 AI143407NIAID NIH HHS R21 AI166396NIAID NIH HHS U01 AI169587NIH HHS DP5 OD023118US National Institutes of Health R01AI181684
6 · The paper itself

Abstract

Yeast display is a widely used technology in antibody discovery and protein engineering. The cell size of yeast enables fluorescence-activated cell sorting (FACS) to precisely screen gene libraries, including for multi-parameter selection of protein phenotypes. However, yeast cells show a broader size distribution than mammalian cells that complicates single-cell gate determination for FACS. In this report, we analyze several yeast display gating options in detail and present an optimized strategy to select single yeast cells via flow cytometry. These data reveal optimized single-cell gating strategies to support robust and high-efficiency yeast display studies.

Indexed as

Flow CytometrySaccharomyces cerevisiaeSingle-Cell Analysisflow cytometrymonoclonal antibodiessingle cellsYeast surface display

Identifiers

PMID39667035
PMCPMC11723770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.